Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers

• Published in: PloS one Vol. 8; no. 6; p. e67484
• Main Authors: Bontjer, Ilja, Melchers, Mark, Tong, Tommy, van Montfort, Thijs, Eggink, Dirk, Montefiori, David, Olson, William C, Moore, John P, Binley, James M, Berkhout, Ben, Sanders, Rogier W
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 26.06.2013; Public Library of Science (PLoS)
• Subjects: AIDS Vaccines - administration & dosage; AIDS Vaccines - immunology; Animals; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Neutralizing - immunology; Antibody Formation - immunology; Antibody response; Antigens; Biology; Clonal deletion; Deletion mutant; Engineering; env Gene Products, Human Immunodeficiency Virus - chemistry; env Gene Products, Human Immunodeficiency Virus - genetics; env Gene Products, Human Immunodeficiency Virus - immunology; Epitopes; Epitopes - immunology; Evolution; Flexible structures; Glycoproteins; HIV; HIV Antibodies - blood; HIV Antibodies - immunology; HIV Infections - immunology; HIV Infections - prevention & control; HIV Infections - virology; HIV-1 - immunology; Human immunodeficiency virus; Humans; Humoral immunity; Hydrophobicity; Immune response; Immune response (humoral); Immune system; Immunity; Immunization; Immunogenicity; Immunoglobulins; Immunology; Infections; Laboratories; Lymphocytes T; Mutants; Neutralization; Neutralization Tests; Protein folding; Proteins; Rabbits; Sequence Deletion; Trimers; Vaccines; Virions; Virology; Viruses; New York; Netherlands; California; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0067484

Despite almost 30 years of research, no effective vaccine has yet been developed against HIV-1. Probably such a vaccine would need to induce both an effective T cell and antibody response. Any vaccine component focused on inducing humoral immunity requires the HIV-1 envelope (Env) glycoprotein complex as it is the only viral protein exposed on the virion surface. HIV-1 has evolved several mechanisms to evade broadly reactive neutralizing antibodies. One such a mechanism involves variable loop domains, which are highly flexible structures that shield the underlying conserved epitopes. We hypothesized that removal of such loops would increase the exposure and immunogenicity of these conserved regions. Env variable loop deletion however often leads to protein misfolding and aggregation because hydrophobic patches becoming solvent accessible. We have therefore previously used virus evolution to acquire functional Env proteins lacking the V1V2 loop. We then expressed them in soluble (uncleaved) gp140 forms. Three mutants were found to perform optimally in terms of protein expression, stability, trimerization and folding. In this study, we characterized the immune responses to these antigens in rabbits. The V1V2 deletion mutant ΔV1V2.9.VK induced a prominent response directed to epitopes that are not fully available on the other Env proteins tested but that effectively bound and neutralized the ΔV1V2 Env virus. This Env variant also induced more efficient neutralization of the tier 1 virus SF162. The immune refocusing effect was lost after booster immunization with a full-length gp140 protein with intact V1V2 loops. Collectively, this result suggests that deletion of variable domains could alter the specificity of the humoral immune response, but did not result in broad neutralization of neutralization-resistant virus isolates.